Literature DB >> 30400835

33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018) : Washington, D.C., USA. 7-11 November 2018.

.   

Abstract

Entities:  

Year:  2018        PMID： 30400835      PMCID： PMC6220480          DOI： 10.1186/s40425-018-0422-y

Source DB:  PubMed          Journal:  J Immunother Cancer        ISSN： 2051-1426            Impact factor:   13.751


× No keyword cloud information.
  7 in total

Review 1.  Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors.

Authors:  Ning Zhu; Shanshan Weng; Juan Wang; Jiaqi Chen; Linzhen Yu; Xuefeng Fang; Ying Yuan
Journal:  J Cancer Res Clin Oncol       Date:  2019-10-15       Impact factor: 4.553

Review 2.  STING pathway agonism as a cancer therapeutic.

Authors:  Blake A Flood; Emily F Higgs; Shuyin Li; Jason J Luke; Thomas F Gajewski
Journal:  Immunol Rev       Date:  2019-07       Impact factor: 12.988

3.  Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.

Authors:  Lawrence Fong; Andrew Hotson; John D Powderly; Mario Sznol; Rebecca S Heist; Toni K Choueiri; Saby George; Brett G M Hughes; Matthew D Hellmann; Dale R Shepard; Brian I Rini; Shivaani Kummar; Amy M Weise; Matthew J Riese; Ben Markman; Leisha A Emens; Daruka Mahadevan; Jason J Luke; Ginna Laport; Joshua D Brody; Leonel Hernandez-Aya; Philip Bonomi; Jonathan W Goldman; Lyudmyla Berim; Daniel J Renouf; Rachel A Goodwin; Brian Munneke; Po Y Ho; Jessica Hsieh; Ian McCaffery; Long Kwei; Stephen B Willingham; Richard A Miller
Journal:  Cancer Discov       Date:  2019-11-15       Impact factor: 38.272

Review 4.  The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.

Authors:  Lea Skak Filtenborg Frederiksen; Yibang Zhang; Camilla Foged; Aneesh Thakur
Journal:  Front Immunol       Date:  2020-07-21       Impact factor: 7.561

Review 5.  Engineering of chimeric natural killer cell receptors to develop precision adoptive immunotherapies for cancer.

Authors:  J Obajdin; D M Davies; J Maher
Journal:  Clin Exp Immunol       Date:  2020-07-25       Impact factor: 4.330

6.  Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181).

Authors:  John Powderly; Alexander Spira; Shunsuke Kondo; Toshihiko Doi; Jason J Luke; Drew Rasco; Bo Gao; Minna Tanner; Philippe A Cassier; Anas Gazzah; Antoine Italiano; Diego Tosi; Daniel E Afar; Apurvasena Parikh; Benjamin Engelhardt; Stefan Englert; Stacie L Lambert; Sreeneeranj Kasichayanula; Sven Mensing; Rajeev Menon; Gregory Vosganian; Anthony Tolcher
Journal:  Clin Transl Sci       Date:  2020-12-26       Impact factor: 4.689

7.  STING Agonist Combined to a Protein-Based Cancer Vaccine Potentiates Peripheral and Intra-Tumoral T Cell Immunity.

Authors:  Matteo Rossi; Susanna Carboni; Wilma Di Berardino-Besson; Erika Riva; Marie-Laure Santiago-Raber; Elodie Belnoue; Madiha Derouazi
Journal:  Front Immunol       Date:  2021-07-01       Impact factor: 7.561
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.